3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
31
Triple Negative Breast Neoplasms
25
Carcinoma, Transitional Cell
9
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
7
Neoplasm Metastasis
7
Lung Neoplasms
4
Endometrial Neoplasms
3
Brain Neoplasms
3
Small Cell Lung Carcinoma
2
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urothelial Bladder Carcinoma
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Interventions
pembrolizumab
1
Paclitaxel
1
Doxorubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
HER2-negative Breast Cancer
×
sacituzumab govitecan
×
1 year
×
Clear all
No trials found.